254 related articles for article (PubMed ID: 29649853)
1. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study.
Germain DP; Brand E; Burlina A; Cecchi F; Garman SC; Kempf J; Laney DA; Linhart A; Maródi L; Nicholls K; Ortiz A; Pieruzzi F; Shankar SP; Waldek S; Wanner C; Jovanovic A
Mol Genet Genomic Med; 2018 Apr; 6(4):492-503. PubMed ID: 29649853
[TBL] [Abstract][Full Text] [Related]
2. Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation.
Lavalle L; Thomas AS; Beaton B; Ebrahim H; Reed M; Ramaswami U; Elliott P; Mehta AB; Hughes DA
PLoS One; 2018; 13(4):e0193550. PubMed ID: 29621274
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry.
Hopkin RJ; Cabrera GH; Jefferies JL; Yang M; Ponce E; Brand E; Feldt-Rasmussen U; Germain DP; Guffon N; Jovanovic A; Kantola I; Karaa A; Martins AM; Tøndel C; Wilcox WR; Yoo HW; Burlina AP; Mauer M
Mol Genet Metab; 2023 Feb; 138(2):106967. PubMed ID: 36709533
[TBL] [Abstract][Full Text] [Related]
4. α-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease.
Oder D; Liu D; Hu K; Üçeyler N; Salinger T; Müntze J; Lorenz K; Kandolf R; Gröne HJ; Sommer C; Ertl G; Wanner C; Nordbeck P
Circ Cardiovasc Genet; 2017 Oct; 10(5):. PubMed ID: 29018006
[TBL] [Abstract][Full Text] [Related]
5. Migalastat Treatment in a Kidney-Transplanted Patient with Fabry Disease and N215S Mutation: The First Case Report.
Di Stefano V; Mancarella M; Camporeale A; Regalia A; Ferraresi M; Pisaniello M; Cassinerio E; Pieruzzi F; Motta I
Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959703
[TBL] [Abstract][Full Text] [Related]
6. Two related Chinese Fabry disease patients with a p.N215S pathological variant who presented with nephropathy.
Sheng B; Yim KF; Lau LK; Lee HCH; Fung KSS; Ma KFJ; Chak WL
Mol Genet Metab Rep; 2020 Sep; 24():100596. PubMed ID: 32435590
[TBL] [Abstract][Full Text] [Related]
7. Globotriaosylsphingosine (Lyso-Gb
Alharbi FJ; Baig S; Auray-Blais C; Boutin M; Ward DG; Wheeldon N; Steed R; Dawson C; Hughes D; Geberhiwot T
J Inherit Metab Dis; 2018 Mar; 41(2):239-247. PubMed ID: 29294190
[TBL] [Abstract][Full Text] [Related]
8. An atypical p.N215S variant of Fabry disease with end-stage renal failure.
Sugarman M; Choudhury J; Jovanovic A
Mol Genet Metab Rep; 2018 Jun; 15():43-45. PubMed ID: 30023289
[TBL] [Abstract][Full Text] [Related]
9. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy.
Maron MS; Xin W; Sims KB; Butler R; Haas TS; Rowin EJ; Desnick RJ; Maron BJ
Am J Med; 2018 Feb; 131(2):200.e1-200.e8. PubMed ID: 28943383
[TBL] [Abstract][Full Text] [Related]
10. Use of a rare disease registry for establishing phenotypic classification of previously unassigned
Germain DP; Oliveira JP; Bichet DG; Yoo HW; Hopkin RJ; Lemay R; Politei J; Wanner C; Wilcox WR; Warnock DG
J Med Genet; 2020 Aug; 57(8):542-551. PubMed ID: 32161151
[TBL] [Abstract][Full Text] [Related]
11. The clinical profiles of female patients with Fabry disease in Latin America: A Fabry Registry analysis of natural history data from 169 patients based on enzyme replacement therapy status.
Martins AM; Cabrera G; Molt F; Suárez-Obando F; Valdés RA; Varas C; Yang M; Politei JM
JIMD Rep; 2019 Sep; 49(1):107-117. PubMed ID: 31497488
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.
Choi JH; Lee BH; Heo SH; Kim GH; Kim YM; Kim DS; Ko JM; Sohn YB; Hong YH; Lee DH; Kook H; Lim HH; Kim KH; Kim WS; Hong GR; Kim SH; Park SH; Kim CD; Kim SM; Seo JS; Yoo HW
Medicine (Baltimore); 2017 Jul; 96(29):e7387. PubMed ID: 28723748
[TBL] [Abstract][Full Text] [Related]
13. Early onset of nephrogenic diabetes insipidus due to fabry disease in a child with
Lu Z; Wang Y; Gao L; Lin L; Hu L; Mao J
Heliyon; 2023 May; 9(5):e15993. PubMed ID: 37205992
[TBL] [Abstract][Full Text] [Related]
14. Fabry Disease: prevalence of affected males and heterozygotes with pathogenic
Doheny D; Srinivasan R; Pagant S; Chen B; Yasuda M; Desnick RJ
J Med Genet; 2018 Apr; 55(4):261-268. PubMed ID: 29330335
[TBL] [Abstract][Full Text] [Related]
15. Natural history of the late-onset phenotype of Fabry disease due to the p.F113L mutation.
Azevedo O; Gago MF; Miltenberger-Miltenyi G; Robles AR; Costa MA; Pereira O; Vide AT; Castelo Branco G; Simões S; Guimarães MJ; Salgado A; Sousa N; Cunha D
Mol Genet Metab Rep; 2020 Mar; 22():100565. PubMed ID: 32099817
[TBL] [Abstract][Full Text] [Related]
16. The Spanish Fabry women study: a retrospective observational study describing the phenotype of females with GLA variants.
Sánchez R; Ripoll-Vera T; López-Mendoza M; de Juan-Ribera J; Gimeno JR; Hermida Á; Ruz-Zafra MA; Torregrosa JV; Mora A; García-Pinilla JM; Fortuny E; Aguinaga-Barrilero A; Torra R
Orphanet J Rare Dis; 2023 Jan; 18(1):8. PubMed ID: 36624527
[TBL] [Abstract][Full Text] [Related]
17. Relapsing minimal change disease superimposed on late-onset p.N215S Fabry nephropathy.
Salerno FR; Roggero L; Rossi F; Binaggia A; Bertoli S; Pieruzzi F
Clin Kidney J; 2022 Jan; 15(1):171-173. PubMed ID: 35035949
[TBL] [Abstract][Full Text] [Related]
18. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
Rosa Neto NS; Bento JCB; Pereira RMR
Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
[TBL] [Abstract][Full Text] [Related]
19. Fabry disease caused by the GLA p.Phe113Leu (p.F113L) variant: Natural history in males.
Oliveira JP; Nowak A; Barbey F; Torres M; Nunes JP; Teixeira-E-Costa F; Carvalho F; Sampaio S; Tavares I; Pereira O; Soares AL; Carmona C; Cardoso MT; Jurca-Simina IE; Spada M; Ferreira S; Germain DP
Eur J Med Genet; 2020 Feb; 63(2):103703. PubMed ID: 31200018
[TBL] [Abstract][Full Text] [Related]
20. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
